The immunogenicity of polyethylene glycol: Facts and fiction

Pharmaceutical Research

Volumn 30, Issue 7, 2013, Pages 1729-1734

  Schellekens, Huub ^a   Hennink, Wim E ^a   Brinks, Vera ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

Author keywords

immune assays; immunogenicity; pegylation; therapeutic proteins

Indexed keywords

ASPARAGINASE MACROGOL; BOVINE SERUM ALBUMIN; FREUND ADJUVANT; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; LIPOSOME; MACROGOL; OVALBUMIN; PEGINTERFERON; PEGLOTICASE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; BLOOD DONOR; COMPLEMENT ACTIVATION; DRUG DELIVERY SYSTEM; ENZYME LINKED IMMUNOSORBENT ASSAY; GOUT; HEMAGGLUTINATION; HEPATITIS C; HUMAN; IMMUNOGENICITY; NONHUMAN; PEGYLATION; PLASMA CLEARANCE; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTIBODIES; ANTIBODY FORMATION; DRUG DELIVERY SYSTEMS; HUMANS; LIPOSOMES; POLYETHYLENE GLYCOLS; PROTEINS;

EID: 84878831095     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-013-1067-7     Document Type: Review

References (30)

1. Payne RW, Murphy BM, Manning MC. Product development issues for PEGylated proteins. Pharm Dev Technol. 2011;16(5):423-40.
2. Kang JS, Deluca PP, Lee KC. Emerging PEGylated drugs. Expert Opin Emerg Drugs. 2009;14(2):363-80.
3. Pasut G, Veronese FM. State of the art in PEGylation: the great versatility achieved after forty years of research. J Control Release. 2012;161(2):461-72.
4. Garay RP, El-Gewely R, Armstrong JK, Garratty G, Richette P. Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents. Expert Opin Drug Deliv. 2012;9(11):1319-23.
5. Armstrong JK. The occurrence, induction, specificity and potential effect of antibodies against poly(ethylene glycol). In: Veronese FM, editor. PEGylated protein drugs: basic science and clinical applications [Internet]. Basel: Birkhäuser Basel; 2009 [cited 2012 Dec 14]. page 147-68. Available from: http://rd.springer.com/chapter/10.1007/978-3-7643-8679-5-9
6. Wang X, Ishida T, Kiwada H. Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes. J Control Release. 2007;119(2):236-44. (Pubitemid 46759557)
7. Richter AW, Akerblom E. Antibodies against polyethylene glycol produced in animals by immunization with monomethoxy polyethylene glycol modified proteins. Int Arch Allergy Appl Immunol. 1983;70(2):124-31. (Pubitemid 13171427)
8. Richter AW, Akerblom E. Polyethylene glycol reactive antibodies in man: titer distribution in allergic patients treated with monomethoxy polyethylene glycol modified allergens or placebo, and in healthy blood donors. Int Arch Allergy Appl Immunol. 1984;74(1):36-9. (Pubitemid 14136479)
9. Shimizu T, Ichihara M, Yoshioka Y, Ishida T, Nakagawa S, Kiwada H. Intravenous administration of polyethylene glycol-coated (PEGylated) proteins and PEGylated adenovirus elicits an anti-PEG immunoglobulin M response. Biol Pharm Bull. 2012;35(8):1336-42.
10. Su Y-C, Chen B-M, Chuang K-H, Cheng T-L, Roffler SR. Sensitive quantification of PEGylated compounds by second-generation anti-poly(ethylene glycol) monoclonal antibodies. Bioconjug Chem. 2010;21(7):1264-70.
11. Sherman MR, Williams LD, Sobczyk MA, Michaels SJ, Saifer MGP. Role of the methoxy group in immune responses to mPEG-protein conjugates. Bioconjug Chem. 2012;23(3):485-99.
12. Liu Y, Reidler H, Pan J, Milunic D, Qin D, Chen D, et al. A double antigen bridging immunogenicity ELISA for the detection of antibodies to polyethylene glycol polymers. J Pharmacol Toxicol Methods. 2011;64(3):238-45.
13. Wiberg M, Wang D, Yang L, Kamerud J. Detection of human anti-polyethylene glycol (PEG) antibodies: challenges for method development. http://www.aapsj.org/abstracts/AM-2010/T3292.pdf.
14. Garratty G. Progress in modulating the RBC membrane to produce transfusable universal/stealth donor RBCs. Transfus Med Rev. 2004;18(4):245-56. (Pubitemid 39389023)
15. Garratty G. Modulating the red cell membrane to produce universal/stealth donor red cells suitable for transfusion. Vox Sang. 2008;94(2):87-95.
16. Ganson NJ, Kelly SJ, Scarlett E, Sundy JS, Hershfield MS. Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase. Arthritis Res Ther. 2006;8(1):R12.
17. Tillmann H, Ganson NJ, Patel K, Thompson AJ, Abdelmalek M, Moody T, et al. High prevalence of pre-existing antibodies against polyethylene glycol (PEG) in hepatitis C (HCV) patients which is not associated with impaired response to PEG-interferon. J Hepatol. 2010;52:S129.
18. Sroda K, Rydlewski J, Langner M, Kozubek A, Grzybek M, Sikorski AF. Repeated injections of PEG-PE liposomes generate anti-PEG antibodies. Cell Mol Biol Lett. 2005;10(1):37-47. (Pubitemid 40559058)
19. Tagami T, Uehara Y, Moriyoshi N, Ishida T, Kiwada H. Anti-PEG IgM production by siRNA encapsulated in a PEGylated lipid nanocarrier is dependent on the sequence of the siRNA. J Control Release. 2011;151(2):149-54.
20. Kaminskas LM, McLeod VM, Porter CJH, Boyd BJ. Differences in colloidal structure of PEGylated nanomaterials dictate the likelihood of accelerated blood clearance. J Pharm Sci. 2011;100(11):5069-77.
21. Zhang C, Fan K, Ma X, Wei D. Impact of large aggregated uricases and PEG diol on accelerated blood clearance of PEGylated canine uricase. PLoS One. 2012;7(6):e39659.
22. Goins B, Phillips WT, Klipper R. Repeat injection studies of technetium-99m-labeled peg-liposomes in the same animal. J Liposome Res. 1998;8:265-81. (Pubitemid 28268267)
23. Oussoren C, Storm G. Effect of repeated intravenous administration on circulation kinetics of poly(ethyleneglycol)-liposomes in rats. J Liposome Res. 1998;9:349-55.
24. Ishida T, Maeda R, Ichihara M, Irimura K, Kiwada H. Accelerated clearance of PEGylated liposomes in rats after repeated injections. J Control Release. 2003;88(1):35-42. (Pubitemid 36173950)
25. Laverman P, Carstens MG, Boerman OC, Dams ET, Oyen WJ, Van Rooijen N, et al. Factors affecting the accelerated blood clearance of polyethylene glycol-liposomes upon repeated injection. J Pharmacol Exp Ther. 2001;298(2):607-12. (Pubitemid 32673411)
26. Dams ET, Laverman P, Oyen WJ, Storm G, Scherphof GL, Van Der Meer JW, et al. Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes. J Pharmacol Exp Ther. 2000;292(3):1071-9. (Pubitemid 30136603)
27. Ishida T, Wang X, Shimizu T, Nawata K, Kiwada H. PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner. J Control Release. 2007;122(3):349-55. (Pubitemid 47407760)
28. Schellekens H. How to predict and prevent the immunogenicity of therapeutic proteins. Biotechnol Annu Rev. 2008;14:191-202. (Pubitemid 351903454)
29. Judge A, McClintock K, Phelps JR, Maclachlan I. Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes. Mol Ther. 2006;13(2):328-37. (Pubitemid 43056898)
30. Hamad I, Hunter AC, Szebeni J, Moghimi SM. Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process. Mol Immunol. 2008;46(2):225-32.